[{"orgOrder":0,"company":"Galderma","sponsor":"Certara","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Trifarotene","moa":"RAR-gamma","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Codexis","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"CDX-7108","moa":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"2","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Aimmune Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Peanut (Arachis hypogaea) Allergen-dnfp","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Nestle Health Sciences SA","amount2":0.46999999999999997,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0.46999999999999997,"dosageForm":"Oral Powder","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"12","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Xencor","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"XmAb7195","moa":"IgE","graph1":"Immunology","graph2":"Phase I","graph3":"Aimmune Therapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"Aimmune Therapeutics \/ Aimmune Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Aimmune Therapeutics \/ Aimmune Therapeutics"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Valbiotis","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"TOTUM-63","moa":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Nestle Health Sciences SA","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"9","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"IL-31 alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"Ach release","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Aimmune Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Peanut Allergen Powder-dnfp","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Nestle Health Sciences SA","amount2":1.9299999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":1.9299999999999999,"dosageForm":"Powder","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"12","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Peanut Allergen Powder-dnfp","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Peanut Allergen Powder-dnfp","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder in capsule","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Senda Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Nutritional therapies","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"4","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Firmicute species bacterial spores","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Encapsulated purified suspension","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"10","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Arachis hypogaea allergen powder-dnfp","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral powder in capsules","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable Gel Implant","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Firmicute Species Bacterial Spores","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nestle Health Sciences SA","amount2":0.53000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.53000000000000003,"dosageForm":"Oral","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"10","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Arachis Hypogaea Allergen Powder-dnfp","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Arachis Hypogaea Allergen Powder-dnfp","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"IL-31 alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Codexis","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"CDX-7108","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"6","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Arachis Hypogaea Allergen Powder-dnfp","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder In Capsule","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Arachis Hypogaea Allergen Powder-dnfp","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Alastin Skincare","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Palmitoyl Tripeptide-1","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Galderma","sponsor":"Alastin Skincare","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Acquisition","leadProduct":"Palmitoyl Tripeptide-1","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Galderma","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Benzoyl Peroxide","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Topical Solution","sponsorNew":"Galderma \/ Taro Pharmaceutical Industries","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Taro Pharmaceutical Industries"},{"orgOrder":0,"company":"Galderma","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"Ach release","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Galderma \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Ipsen"},{"orgOrder":0,"company":"Galderma","sponsor":"Sol-Gel Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Benzoyl Peroxide","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Bioiberica","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Hyaluronic Acid","moa":"","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Nestle Health Sciences SA \/ Bioiberica","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Bioiberica"},{"orgOrder":0,"company":"GALDERMA LABS LP","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Approved","graph3":"GALDERMA LABS LP","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"GALDERMA LABS LP \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GALDERMA LABS LP \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"Ach","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"BotulinumtoxinA","moa":"Ach","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Arachis Hypogaea","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"IL-31","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Enterome","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"EB1010","moa":"IL-10","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"4","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"IL-31","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"BotulinumtoxinA","moa":"ACh","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Allergy Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Arachis Hypogaea","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Aimmune Therapeutics \/ Allergy Partners","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Therapeutics \/ Allergy Partners"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Codexis","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"CDX-7108","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"6","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Fecal Microbiota Spores Live-brpk","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"12","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Valbiotis","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"TOTUM\u202263","moa":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"9","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Fecal Microbiota Spores Live-brpk","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nestle Health Sciences SA","amount2":0.53000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.53000000000000003,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"12","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Fecal Microbiota Spores Live-brpk","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"12","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Galderma","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Large molecule","year":"2023","type":"Termination","leadProduct":"Botulinum toxin type A","moa":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Galderma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"7","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Galderma","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Codexis","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"CDX-7108","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Nestle Health Sciences SA","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Nestle Health Sciences SA \/ Codexis","highestDevelopmentStatusID":"6","companyTruncated":"Nestle Health Sciences SA \/ Codexis"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"RelabotulinumtoxinA","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"RelabotulinumtoxinA","moa":"","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Fecal Microbiota Spores Live","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"12","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"RelabotulinumtoxinA","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"RelabotulinumtoxinA","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"RelabotulinumtoxinA","moa":"","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31 alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Nestle Health Sciences SA
Details :
Nemluvio (nemolizumab) is a humanized anti-human IL-31 receptor A monoclonal antibody, approved for the treatment of patients with moderate-to-severe atopic dermatitis.
Details :
Relfydess (relabotulinumtoxinA) is the first and only ready-to-use liquid neuromodulator created with PEARL™ Technology for moderate to severe vertical frown lines.
Details :
Nemluvio (nemolizumab) is a humanized anti-human IL-31 receptor A monoclonal antibody, approved for the treatment of patients with moderate-to-severe atopic dermatitis & prurigo nodularis.
Details :
Nemluvio (nemolizumab) is a humanized anti-human IL-31 receptor A monoclonal antibody, approved for the treatment of patients with moderate-to-severe atopic dermatitis.
Details :
Relfydess (relabotulinumtoxinA) is the first and only ready-to-use liquid neuromodulator created with PEARL™ Technology for moderate to severe vertical frown lines.
Details :
Nemluvio (nemolizumab) is a humanized anti-human IL-31 receptor A monoclonal antibody, approved for the treatment of patients with prurigo nodularis.
Details :
Relfydess (relabotulinumtoxinA) is the first and only ready-to-use liquid neuromodulator created with PEARL™ Technology for moderate to severe vertical frown lines.
Details :
Nestlé will acquire certain assets associated with VOWST (fecal microbiota spores), the first and only FDA approved oral therapeutic to prevent recurrence of Clostridioides difficile infection.
Details :
QM1114-DP (relabotulinumtoxinA) is a botulinum toxin neuromodulator, which is under phase 3 clinical development for the treatment of glabellar frown lines & lateral canthal lines.
Reset All
